Cargando…
Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider
Chemotherapeutic agents and radiation therapy are associated with numerous potential adverse events (AEs). Many of these common AEs, namely chemotherapy- or radiation-induced nausea and vomiting, hypersensitivity reactions, and edema, can lead to deleterious outcomes (such as treatment nonadherence...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631343/ https://www.ncbi.nlm.nih.gov/pubmed/35295545 http://dx.doi.org/10.6004/jadpro.2021.12.8.4 |
_version_ | 1784607539969654784 |
---|---|
author | Clemmons, Amber Gandhi, Arpita Clarke, Andrea Jimenez, Sarah Le, Thuy Ajebo, Germame |
author_facet | Clemmons, Amber Gandhi, Arpita Clarke, Andrea Jimenez, Sarah Le, Thuy Ajebo, Germame |
author_sort | Clemmons, Amber |
collection | PubMed |
description | Chemotherapeutic agents and radiation therapy are associated with numerous potential adverse events (AEs). Many of these common AEs, namely chemotherapy- or radiation-induced nausea and vomiting, hypersensitivity reactions, and edema, can lead to deleterious outcomes (such as treatment nonadherence or cessation, or poor clinical outcomes) if not prevented appropriately. The occurrence and severity of these AEs can be prevented with the correct prescribing of prophylactic medications, often called “premedications.” The advanced practitioner in hematology/oncology should have a good understanding of which chemotherapeutic agents are known to place patients at risk for these adverse events as well as be able to determine appropriate prophylactic medications to employ in the prevention of these adverse events. While several guidelines and literature exist regarding best practices for prophylaxis strategies, differences among guidelines and quality of data should be explored in order to accurately implement patient-specific recommendations. Herein, we review the existing literature for prophylaxis and summarize best practices |
format | Online Article Text |
id | pubmed-8631343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Harborside Press LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-86313432022-03-15 Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider Clemmons, Amber Gandhi, Arpita Clarke, Andrea Jimenez, Sarah Le, Thuy Ajebo, Germame J Adv Pract Oncol Review Chemotherapeutic agents and radiation therapy are associated with numerous potential adverse events (AEs). Many of these common AEs, namely chemotherapy- or radiation-induced nausea and vomiting, hypersensitivity reactions, and edema, can lead to deleterious outcomes (such as treatment nonadherence or cessation, or poor clinical outcomes) if not prevented appropriately. The occurrence and severity of these AEs can be prevented with the correct prescribing of prophylactic medications, often called “premedications.” The advanced practitioner in hematology/oncology should have a good understanding of which chemotherapeutic agents are known to place patients at risk for these adverse events as well as be able to determine appropriate prophylactic medications to employ in the prevention of these adverse events. While several guidelines and literature exist regarding best practices for prophylaxis strategies, differences among guidelines and quality of data should be explored in order to accurately implement patient-specific recommendations. Herein, we review the existing literature for prophylaxis and summarize best practices Harborside Press LLC 2021-11 2021-11-01 /pmc/articles/PMC8631343/ /pubmed/35295545 http://dx.doi.org/10.6004/jadpro.2021.12.8.4 Text en © 2021 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Clemmons, Amber Gandhi, Arpita Clarke, Andrea Jimenez, Sarah Le, Thuy Ajebo, Germame Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider |
title | Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider |
title_full | Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider |
title_fullStr | Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider |
title_full_unstemmed | Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider |
title_short | Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider |
title_sort | premedications for cancer therapies: a primer for the hematology/oncology provider |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631343/ https://www.ncbi.nlm.nih.gov/pubmed/35295545 http://dx.doi.org/10.6004/jadpro.2021.12.8.4 |
work_keys_str_mv | AT clemmonsamber premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider AT gandhiarpita premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider AT clarkeandrea premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider AT jimenezsarah premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider AT lethuy premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider AT ajebogermame premedicationsforcancertherapiesaprimerforthehematologyoncologyprovider |